Last updated: May 29, 2026
Executive summary: Prochlorperazine edisylate is sourced through (1) API and salt-manufacturing suppliers supplying global pharma manufacturers and contract manufacturers, (2) intermediate producers that support route-critical steps for prochlorperazine and salt formation, and (3) finished-dose supply from branded and generic tablet/solution manufacturers. The usable supplier universe depends on whether you need regulated, audit-ready API (DMF/CEP-backed), late-stage dosage-form contract manufacturing, or commercial packaged product.
Who supplies prochlorperazine edisylate API and salt (edisylate) for pharma?
Direct answer: Prochlorperazine edisylate is typically supplied as API in the edisylate salt form by specialty generics and API manufacturers, then qualified by downstream finished-dose firms. The salt-form supply chain is integrated with prochlorperazine API production and salt conversion, because edisylate formation must match specific polymorph, particle-size, and moisture specs set by the finished-dose manufacturer’s development and regulatory package.
What categories of suppliers exist for prochlorperazine edisylate?
- API manufacturers (with salt form)
Supply prochlorperazine free base and convert to edisylate or supply the edisylate salt directly to customers under cGMP.
- Specialty salt and intermediate suppliers
Provide inputs for the route that lead to prochlorperazine formation or support salt conversion controls.
- Finished-dose manufacturers
Produce prochlorperazine edisylate tablets and other dosage forms under cGMP for branded and generic markets.
Which supplier qualification artifacts matter in practice?
- DMF (Drug Master File) or equivalent regulatory documentation linking to edisylate-form API specifications.
- CoA + batch traceability tied to salt-form acceptance criteria.
- Polymorph/solid-state controls (for salt form).
- Stability program for edisylate API under relevant humidity and temperature conditions.
What finished-dose manufacturers supply prochlorperazine edisylate tablets or injectable products?
Direct answer: Finished-dose supply is split between (1) historical brand/legacy manufacturers and (2) generic tablet manufacturers with multiple ANDA approvals for prochlorperazine formulations. Injectable supply is more sensitive to sterile manufacturing controls and lot release.
Which dosage forms are typically in the supplier mix?
- Tablets (most common commercial form)
- Oral liquid/solution (where marketed)
- Sterile injectable solutions (where the market supports it)
How do dosage-form supply decisions affect IP and sourcing?
Finished-dose entrants typically source API under either:
- commercial API supply agreements (multiple-source), or
- customer-specific API supply tied to a regulatory submission and the company’s validated manufacturing process.
If a finished-dose firm has an FDA regulatory filing tied to a particular API manufacturer and process, switching API sources can require bridging work and change-management under comparability and CMC controls.
How many supplier options exist globally for prochlorperazine edisylate?
Direct answer: The supplier count is usually higher for tablet-grade prochlorperazine API than for edsisylate-specific API with tightly controlled solid state specifications. In practice, the market tends to consolidate around a smaller set of API suppliers that can consistently deliver edisylate salt properties suitable for downstream bioavailability and stability.
What drives consolidation?
- Salt-form solid-state variability risk
- End-product humidity sensitivity
- DMF readiness and inspection history
- Customer audit acceptance and supply continuity
What is the Orange Book and FDA regulatory status of prochlorperazine edisylate products that indicates supplier readiness?
Direct answer: FDA regulatory status is product-specific. Prochlorperazine edisylate appears in branded and generic listings depending on dosage form, strength, and route of administration. Supplier-readiness signals are best inferred from whether multiple ANDA applicants exist for the same dosage form, implying multiple qualified API and CMC routes.
What to look for on FDA product pages
- Product dosage form and strength coverage
- Approved application type (NDA vs ANDA)
- Labeling changes and controlled-substance scheduling (if any, often none)
- Supplier-related CMC references (in the sponsor/manufacturer section)
(Note: A complete, defensible supplier table requires Orange Book and label-level verification for each specific marketed strength and dosage form.)
Which suppliers are likely preferred by contract manufacturers for prochlorperazine edisylate?
Direct answer: Contract manufacturing organizations for tablets and solutions tend to qualify suppliers that provide:
- edisylate API at scale,
- consistent impurity profiles aligned with their finished-dose method,
- regulatory-grade documentation (DMF linking, audit readiness),
- stable supply lead times.
Procurement filters that reduce delivery risk
- validated salt-form specs (identity, assay, water content, particle size where relevant)
- impurity thresholds and CP/USP methods fit
- QC release speed and incoming testing turnaround
- ability to support accelerated stability batches for change-control
How do API intermediates and prochlorperazine free base suppliers fit into edisylate supply?
Direct answer: Even when the commercial purchase is prochlorperazine edisylate, many supply contracts include:
- prochlorperazine free base manufacturing upstream, and
- salt conversion steps downstream (either at the API site or by a salt-form partner under the same quality system).
Why salt conversion matters commercially
- Editsylate salt formation can change solubility and stability, which drives end-product dissolution and shelf life.
- Salt conversion and drying can impact residual solvent/water, which affects finished-dose performance.
What are typical commercial contracting structures for prochlorperazine edisylate supply?
Direct answer: Most procurement models fall into one of three patterns:
- Long-term supply with quality agreement (preferred for shortage risk)
- Qualified vendor list (QVL) with periodic requalification
- Project-based supply tied to a specific ANDA/CMC submission
Key contract terms
- minimum batch size and annual volume commitment
- change-control notification windows for process or site changes
- right to audit and sampling frequency
- batch rejection and remediation clauses
Key Takeaways
- Prochlorperazine edisylate sourcing typically runs through API manufacturers capable of reproducible edisylate salt production and solid-state control.
- Finished-dose suppliers often qualify a limited number of API vendors because salt-form specifications must match validated CMC controls.
- The supplier universe differs by dosage form and route: tablets generally have broader sourcing; sterile injectable supply is more constrained.
- Defensible supplier selection requires regulatory-ready API documentation and audit/CoA consistency tied to edisylate salt specifications.
FAQs
- What specs distinguish prochlorperazine edisylate API from prochlorperazine free base?
- Can a finished-dose manufacturer switch API suppliers for prochlorperazine edisylate without major CMC changes?
- What drives shortages or supply disruptions for prochlorperazine edisylate?
- How do polymorph and water-content controls impact edisylate API and finished-dose stability?
- Which supplier documents are most important for API qualification in an ANDA CMC package?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drugs@FDA. U.S. Food and Drug Administration.
